Sara Tyebally

Jan 10, 2025 | sciencedirect.com | Sara Tyebally |Avirup Guha |Derya Tilki |Philip Cornford

© 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Jun 6, 2024 | onlinelibrary.wiley.com | Aderonke T Abiodun |Marianne Jane Shawe-Taylor |Sara Tyebally |Emmanouil Bagkeris

Introduction Fluoropyrimidines including 5-fluorouracil (5-FU) and capecitabine are the third most common cancer treatment class used worldwide.1 They form the basis of chemotherapy treatment for gastrointestinal malignancies, breast, pancreatic and head and neck cancers.2-4 For many patients who develop complications with 5-FU, alternative cancer treatment options are very limited, particularly in colorectal cancer where 5-FU is a backbone of first- and second-line chemotherapy, and...